IL1B and rheumatoid arthritis: In addition, IL inhibitors such as anakinra, rilonacept, canakinumab, tocilizumab, and ustekinumab exert influence on IL-1, IL-1 beta, IL-6, IL-12, and IL-23, and abatacept, which suppresses CTLA-4, has also been shown to have a persuasive action in RA pathogenesis [1].